On November 22, the release ceremony of the 11th Top 100 Ranking of China's Pharmaceutical Industry guided by CFDA Southern Medicine Economic Research Institute and hosted by Pharmaceutical Economic News was grandly held in Guangzhou. Hansoh Pharma was ranked 18th among Top 100.
In recent years, Hansoh Pharma has closely followed the national pharmaceutical policy, taken multiple measures to accelerate the transformation and upgrading of the company, and rapidly improved its comprehensive strength, with annual sales growth higher than the industry average; it has actively promoted its go-global strategy, and obtained the US FDA certification for its two anti-tumor injections Zefei and Gainuo and the Japan PMDA certification for its anti-tumor injection Pulaille, becoming one of the first domestic pharmaceutical companies approved to market and sell injections in developed markets in Europe, the US and Japan.
During the 13th Five Year Plan period, Hansoh Pharma will continue to accelerate supply-side reform measures such as transformation and upgrading, promote the sustainable development strategy of "technological innovation" and "go-global", and strive to grow into a first-class multinational pharmaceutical enterprise group.
Notes:
1. The time span of this ranking is from January 1 to December 31, 2015.
2. The statistical indicator caliber of this ranking is the amount of annual sales revenue of enterprises in the pharmaceutical industry （according to Chinese accounting standards）。
3. Participants in the ranking are pharmaceutical industrial enterprises registered in China （excluding subsidiaries of multinational pharmaceutical enterprises in China） with pharmaceutical manufacturing as their main business, namely, companies whose pharmaceutical manufacturing business is at the top of their main business scope in their industrial and commercial registration. If any participant is engaged in pharmaceutical commerce or other non-pharmaceutical operations, such operations are excluded in statistics;
4. In the ranking, statistics are performed for each enterprise group. In the ranking, statistics are preferably based on group companies or listed companies. If a group company contains a listed company, statistics are preferably based on the group company. With regard to a group company, the scope of statistics includes any wholly-owned subsidiary of the group company and any company in which the group company holds more than 50% shares, directly or indirectly; any company in which the group company holds non-controlling shares is not included in statistics.
